Paul Tudor Jones Zentalis Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 35,169 shares of ZNTL stock, worth $62,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,169
Previous 35,709
1.51%
Holding current value
$62,952
Previous $131,000
19.08%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ZNTL
# of Institutions
147Shares Held
65.3MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$25 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$8.63 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$8.01 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$5.86 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$5.76 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $102M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...